Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 4/20 | 0.67 |
| ▸ | JAK3 | P52333 | 4/20 | 0.67 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.67 |
| ▸ | CYP2C8 | P10632 | 3/20 | 0.67 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.67 |
| ▸ | JAK1 | P23458 | 3/20 | 0.67 |
| ▸ | TYK2 | P29597 | 3/20 | 0.67 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.67 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.67 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.67 |
| ▸ | AURKA | O14965 | 3/20 | 0.42 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.42 |
| ▸ | GRK6 | P43250 | 2/20 | 0.41 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.40 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.40 |
| ▸ | CDK2 | P24941 | 1/20 | 0.40 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.39 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | CLK1 | P49759 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL174280 | 1.00 | JAK2 (0.67) | JAK2JAK3CYP3A4CYP2C8CYP2C9 | |
| SCHEMBL15205991 | 1.00 | JAK2 (0.67) | JAK2JAK3CYP3A4CYP2C8CYP2C9 | |
| SCHEMBL15205990 | 1.00 | JAK2 (0.67) | JAK2JAK3CYP3A4CYP2C8CYP2C9 | |
| Hydrochloric Acid SCHEMBL174359 | 0.99 | JAK2 (0.66) | JAK2JAK3CYP3A4CYP2C8CYP2C9 | |
| Hydrochloric Acid SCHEMBL174357 | 0.99 | JAK2 (0.66) | JAK2JAK3CYP3A4CYP2C8CYP2C9 | |
| Hydrochloric Acid SCHEMBL174358 | 0.99 | JAK2 (0.66) | JAK2JAK3CYP3A4CYP2C8CYP2C9 | |
| SCHEMBL174606 | 0.81 | JAK2 (0.69) | JAK2JAK3CYP3A4CYP2C8CYP2C9 | |
| SCHEMBL187195 | 0.81 | JAK2 (0.69) | JAK2JAK3CYP3A4CYP2C8CYP2C9 | |
| SCHEMBL187194 | 0.81 | JAK2 (0.69) | JAK2JAK3CYP3A4CYP2C8CYP2C9 | |
| SCHEMBL10224867 | 0.81 | JAK2 (0.69) | JAK2JAK3CYP3A4CYP2C8CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130225614-A1 | 4-AZOLYLAMINOQUINAZOLINE DERIVATIVES AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORPORATION (US) | 2013-08-29 | — | — | US | claimed |
| EP-3179992-B1 | THERAPEUTIC COMBINATIONS OF A BTK INHIBITOR, A PD-1 INHIBITOR AND/OR A PD-L1 INHIBITOR | ACERTA PHARMA BV (NL) | 2022-05-11 | — | — | EP | disclosed |
| US-20220088013-A1 | Therapeutic Combinations of a BTK Inhibitor, a PI3K Inhibitor, a JAK-2 Inhibitor, and/or a BCL-2 Inhibitor | ACERTA PHARMA B.V. (NL) | 2022-03-24 | — | — | US | disclosed |
| US-11166951-B2 | Therapeutic combinations of a BTK inhibitor, a PI3K inhibitor, a JAK-2 inhibitor, and/or a BCL-2 inhibitor | ACERTA PHARMA B.V. (NL) | 2021-11-09 | — | — | US | disclosed |
| EP-3179991-B1 | THERAPEUTIC COMBINATIONS OF A BTK INHIBITOR AND A BCL-2 INHIBITOR | ACERTA PHARMA BV (NL) | 2021-10-06 | — | — | EP | disclosed |
| US-20200069796-A1 | Therapeutic Combinations of a BTK Inhibitor, a PI3K Inhibitor, a JAK-2 Inhibitor, a PD-1 Inhibitor, and/or a PD-L1 Inhibitor | ACERTA PHARMA BV (NL) | 2020-03-05 | — | — | US | disclosed |
| US-20180250298-A1 | Therapeutic Combinations of a BTK Inhibitor, a PI3K Inhibitor, a JAK-2 Inhibitor, and/or a BCL-2 Inhibitor | ACERTA PHARMA BV (NL) | 2018-09-06 | — | — | US | disclosed |
| US-20180250400-A1 | Therapeutic Combinations of a BTK Inhibitor, a PI3K Inhibitor, a JAK-2 Inhibitor, and/or a CDK4/6 Inhibitor | ACERTA PHARMA BV (NL) | 2018-09-06 | — | — | US | disclosed |
| US-20180207154-A1 | Therapeutic Combinations of a BTK Inhibitor, a PI3K Inhibitor and/or a JAK-2 Inhibitor | ACERTA PHARMA BV (NL) | 2018-07-26 | — | — | US | disclosed |
| US-9949971-B2 | Therapeutic combinations of a BTK inhibitor, a PI3K inhibitor and/or a JAK-2 inhibitor | ACERTA PHARMA B.V. (NL) | 2018-04-24 | — | — | US | disclosed |
| US-20170239351-A1 | Therapeutic Combinations of a BTK Inhibitor, a PI3K Inhibitor, a JAK-2 Inhibitor, a PD-1 Inhibitor, and/or a PD-L1 Inhibitor | ACERTA PHARMA BV (NL) | 2017-08-24 | — | — | US | disclosed |
| US-20170231986-A1 | Therapeutic Combinations of a BTK Inhibitor, a PI3K Inhibitor, a JAK-2 Inhibitor, and/or a BCL-2 Inhibitor | ACERTA PHARMA B.V. (NL) | 2017-08-17 | — | — | US | disclosed |
| US-20170224819-A1 | Therapeutic Combinations of a BTK Inhibitor, a PI3K Inhibitor, a JAK-2 Inhibitor, and/or a CDK 4/6 Inhibitor | ACERTA PHARMA BV (NL) | 2017-08-10 | — | — | US | disclosed |
| US-20170136014-A1 | Therapeutic Combinations of a BTK Inhibitor, a PI3K Inhibitor and/or a JAK-2 Inhibitor | ACERTA PHARMA BV (NL) | 2017-05-18 | — | — | US | disclosed |
| US-20130225614-A1 | 4-AZOLYLAMINOQUINAZOLINE DERIVATIVES AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORPORATION (US) | 2013-08-29 | — | — | US | disclosed |
| US-20130225614-A1 | 4-AZOLYLAMINOQUINAZOLINE DERIVATIVES AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORPORATION (US) | 2013-08-29 | — | — | US | disclosed |
| US-20130225614-A1 | 4-AZOLYLAMINOQUINAZOLINE DERIVATIVES AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORPORATION (US) | 2013-08-29 | — | — | US | disclosed |
| WO-2012030914-A1 | 4-AZOLYLAMINOQUINAZOLINE DERIVATIVES AND METHODS OF USE THEREOF | AMBIT BOISCIENCES CORPORATION (US) | 2012-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170231986-A1 | Therapeutic Combinations of a BTK Inhibitor, a PI3K Inhibitor, a JAK-2 Inhibitor, and/or a BCL-2 Inhibitor | BTK, JAK2, BCL9 | JAK2 2/4885JAK3 8/4885CYP3A4 2996/4885 |
| US-20170136014-A1 | Therapeutic Combinations of a BTK Inhibitor, a PI3K Inhibitor and/or a JAK-2 Inhibitor | BTK, JAK2, JAK1 | JAK2 2/4885JAK3 4/4885CYP3A4 2985/4885 |
| US-11166951-B2 | Therapeutic combinations of a BTK inhibitor, a PI3K inhibitor, a JAK-2 inhibitor, and/or a BCL-2 inhibitor | BTK, JAK2, BCL9 | JAK2 2/4885JAK3 8/4885CYP3A4 2996/4885 |
| US-20220088013-A1 | Therapeutic Combinations of a BTK Inhibitor, a PI3K Inhibitor, a JAK-2 Inhibitor, and/or a BCL-2 Inhibitor | BTK, JAK2, BCL9 | JAK2 2/4885JAK3 8/4885CYP3A4 2996/4885 |
| US-20180250298-A1 | Therapeutic Combinations of a BTK Inhibitor, a PI3K Inhibitor, a JAK-2 Inhibitor, and/or a BCL-2 Inhibitor | BTK, JAK2, BCL9 | JAK2 2/4885JAK3 8/4885CYP3A4 2996/4885 |
| US-20170239351-A1 | Therapeutic Combinations of a BTK Inhibitor, a PI3K Inhibitor, a JAK-2 Inhibitor, a PD-1 Inhibitor, and/or a PD-L1 Inhibitor | BTK, JAK1, PDCD1 | JAK2 4/4885JAK3 7/4885CYP3A4 4502/4885 |
| US-20130225614-A1 | 4-AZOLYLAMINOQUINAZOLINE DERIVATIVES AND METHODS OF USE THEREOF | JAK2, JAK3, JAK1 | JAK2 1/4885JAK3 2/4885CYP3A4 2057/4885 |
| US-20180250400-A1 | Therapeutic Combinations of a BTK Inhibitor, a PI3K Inhibitor, a JAK-2 Inhibitor, and/or a CDK4/6 Inhibitor | BTK, JAK2, CDK4 | JAK2 2/4885JAK3 7/4885CYP3A4 1885/4885 |
| US-20170224819-A1 | Therapeutic Combinations of a BTK Inhibitor, a PI3K Inhibitor, a JAK-2 Inhibitor, and/or a CDK 4/6 Inhibitor | BTK, CDK6, CDK4 | JAK2 4/4885JAK3 9/4885CYP3A4 1539/4885 |
| US-20200069796-A1 | Therapeutic Combinations of a BTK Inhibitor, a PI3K Inhibitor, a JAK-2 Inhibitor, a PD-1 Inhibitor, and/or a PD-L1 Inhibitor | BTK, JAK1, PDCD1 | JAK2 4/4885JAK3 7/4885CYP3A4 4502/4885 |
| US-20180207154-A1 | Therapeutic Combinations of a BTK Inhibitor, a PI3K Inhibitor and/or a JAK-2 Inhibitor | BTK, JAK2, JAK1 | JAK2 2/4885JAK3 5/4885CYP3A4 2824/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.